|Table of Contents|

Safety and efficacy of allogeneic NK cells in the treatment of metastatic gastrointestinal malignant ascites(3 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
646-651
Research Field:
Publishing date:

Info

Title:
Safety and efficacy of allogeneic NK cells in the treatment of metastatic gastrointestinal malignant ascites(3 cases)
Author(s):
ZHANG Ke1; FANG Juemin1; YANG Juan2; LIU Gentao1; 2; LI Jiyu1; XU Qing1
1.Department of Oncology,Shanghai Tenth People's Hospital Affiliated to Tongji University,Shanghai 200072,China；2.Shanghai Biomed-union Biotechnology Co.Ltd,Shanghai 201321,China.
Keywords:
NK cell; metastatic gastrointestinal carcinoma; malignant ascites; cellular immunotherapy
PACS:
R730.51
DOI:
10.3969/j.issn.1672-4992.2022.04.018
Abstract:
Objective:To evaluate the safety and clinical efficacy of 3 patients with malignant ascites caused by metastatic gastrointestinal tumors treated with allogenetic NK cells.Methods:We collected the clinical data of three patients with malignant ascites caused by metastatic gastrointestinal carcinoma treated with allogenetic NK cells in our hospital.The changes in IL-6,IL-8,IL-10,TNF-α,lymphocyte subsets,tumor markers in peripheral blood of patients,ECC in ascites and patients' improvements of ascites symptoms were observed at pre-treatment and 2 weeks post-treatment.Adverse events of patients were also evaluated.Results:No serious infusion-related side effects were observed in all 3 patients.The IL-8 of 3 patients decreased significantly after allogeneic NK cell treatment.The depth of ascites,ascites ECC,peripheral blood CEA and CA199 decreased significantly in 1 patient after allogeneic NK cell treatment.No significant change was observed in lymphocyte subsets in 3 patients.Conclusion:Three patients with malignant ascites caused by metastatic digestive tract tumors treated with allogeneic NK cells were safe and without serious side effects.Allogeneic NK cell therapy may be effective in 1 patient.The clinical efficacy of allogeneic NK cell therapy needs to be further verified.

References:

[1]FERLAY J，SHIN HR，BRAY F，et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008［J］.Int J Cancer，2010，127(12):2893-2917.
[2]BRAY F，JEMAL A，GREY N，et al.Global cancer transitions according to the Human Development Index(2008-2030):a population-based study［J］.The Lancet Oncology，2012,13(8):790-801.
[3]夏佳薇，何松.消化道早癌筛查技术的研究进展［J］.重庆医学，2019,48(6):1014-1017. XIA JW,HE S.Research progress of screening technology for early cancer of digestive tract［J］.Chongqing Medicine,2019,48(6):1014-1017.
[4]KOEHL U，KALBERER C，SPANHOLTZ J，et al.Advances in clinical NK cell studies:donor selection，manufacturing and quality control［J］.Oncoimmunology，2016，5(4):e1115178.
[5]BERAHOVICH R，ZHOU H，XU S，et al.CAR-T cells based on novel BCMA monoclonal antibody block multiple myeloma cell growth［J］.Cancers(Basel)，2018，10(9):323-338.
[6]VERNERIS MR，KARAMI M，BAKERET J，et al.Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells［J］.Blood，2004，103(8):3065-3072.
[7]DAI C，LIN F，GENG R，et al.Implication of combined PDL-1/PD-1 blockade with cytokine-induced killer［J］.Oncotarget，2016，7(9):10332-10344.
[8]刁爱坡，赵青.肿瘤免疫细胞治疗研究进展［J］.天津科技大学学报，2018，33(1):1-8. DIAO AP,ZHAO Q.Research progress in immune cell-mediated cancer therapy［J］.Journal of Tianjin University of Science & Technology,2018,33(1):1-8.
[9]ADOTEVIA O，GODETA Y，GALAINE J，et al.In situ delivery of allogeneic natural killer cell(NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma:A phase I clinical trial［J］.Oncoimmunology，2018，7(5):e1424673（11pages）.
[10]WANG W，ERBE AK，DESANTES KB，et al.Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy［J］.Future Oncol，2017，13(12):1043-1047.
[11]BJORKLUND AT，CARLSTEN M，SOHLBERG E，et al.Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML［J］.Clin Cancer Res，2018，24(8):1834-1844.
[12]WANG Y，SUN J，GAO W，et al.Preoperative Tim3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer［J］.Mol Med Rep，2017，15(6):3810-3818.
[13]徐成，陈洁平，田小波，等.85例结外鼻型NK/T细胞淋巴瘤治疗及预后的回顾性观察［J］.第三军医大学学报，2018，40(8):723-727. XU C,CHEN JP,TIAN XB,et al.Treatment and outcomes of extranodal natural killer/T cell lymphoma,nasal type:a retrospective analysis of 85 cases［J］.Journal of Third Military Medical University,2018,40(8):723-727.
[14]马冉冉，韩琛，王朝霞，等.人参总皂苷调控NK细胞活性促进5-氟尿嘧啶抗肿瘤的作用［J］.山东大学学报(医学版)，2018，56(4):43-50. MA RR,HAN C,WANG ZX,et al.Total saponins of Panax ginseng promoting the anticancer activity of 5-fluorouracil by mediating NK cell activity［J］.Journal of Shandong University(Health Sciences),2018,56(4):43-50.
[15]周阳阳，秦叔逵，汪蕊，等.阿帕替尼治疗晚期胃癌伴顽固性癌性腹水4例［J］.临床肿瘤学杂志，2016，21(5):476-478. ZHOU YY,QIN SK,WANG R,et al.Apatinib in the treatment of advanced gastric cancer with intractable ascites:a report of 4 cases［J］.Chinese Clinical Oncology,2016,21(5):476-478.
[16]IWASA S，NAKAJIMA TE，NAKAMURA K，et al.First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer［J］.Gastric Cancer，2012，15(1):21-26.
[17]FERLAY J,SOERJOMATARAM I，DIKSHIT R et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer，2015，136(5):E359-E386.
[18]MURPHY WJ，PARHAM P，MILLER JS.NK cells-from bench to clinic［J］.Biology of Blood and Marrow Transplantation，2012，18(1):S2-S7.
[19]ERIC V，ELENA T，MYRIAMET B，et al.Functions of natural killer cells［J］.Nature Immunology，2008，9:503.
[20]REZVANI K，ROUCE RH.The application of natural killer cell immunotherapy for the treatment of cancer［J］.Front Immunol，2015，6:578.
[21]DU Y，WEI Y.Therapeutic potential of natural killer cells in gastric cancer［J］.Front Immunol，2018，9:3095.
[22]STABILE H，FIONDA C，GISMONDI A，et al.Role of distinct natural killer cell subsets in anticancer response［J］.Frontiers in Immunology，2017，8:293.
[23]MARTIN AB，SUNE G，PEREZ AL，et al.Natural killer cells:angels and devils for immunotherapy［J］.International Journal of Molecular Sciences，2017，18(9):1868-1888.
[24]STETSON DB，MOHRS M，REINHARDT RL，et al.Constitutive cytokine mRNAs mark natural killer(NK) and NK T cells poised for rapid ector function［J］.J Exp Med，2003，198(7):1069-1076.
[25]WAJANT H，PFIZENMAIER K，SCHEURICH P.Tumor necrosis factor signaling［J］.Cell death And differentiation，2003,10:45-65.
[26]LANIER LL.NK cell recognition［J］.Annual Review of Immunology，2005，23(1):225-274.
[27]REZVANI K，ROUCE R，LIU E,et al.Engineering natural killer cells for cancer immunotherapy［J］.Mol Ther，2017，25(8):1769-1781.
[28]CHEN Y,SHI M,YU GZ,et al.Interleukin-8,a promising predictor for prognosis of pancreatic cancer［J］.World J Gastroenterol 2012,18:1123-1129.
[29]CHEN JJ,YAO PL,YUAN A,et al.Up-regulation of tumor interleukin-8 expression by infiltrating macrophages:its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer［J］.Clini Cancer Res,2003,9:729-737.
[30]ZHU YM,WEBSTER SJ,FLOWER D,et al.Interleukin-8/CXCL8 is a growth factor for human lung cancer cells［J］.Br J Cancer,2004,91:1970-1976.
[31]SPIRA A,BEANE JE,SHAH V,et al.Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer［J］.Nat Med,2007,13:361-366.
[32]DAVID JM,DOMINGUEZ C,HAMILTON DH,et al.The IL-8/IL-8R axis:a double agent in tumor immune resistance［J］.Vaccines(Basel),2016,4:E22.
[33]TODOROVIC-RAKOVIC N,MILOVANOVIC J.Interleukin-8 in breast cancer progression［J］.Interfer Cytokine Res,2013,33:563-570.
[34]CHENG M，CHEN Y，XIAO W，et al.NK cell-based immunotherapy for malignant diseases［J］.Cell Mol Immunol，2013，10(3):230-252.
[35]TANG X，YANG L，LI Z，et al.First-in-man clinical trial of CAR NK-92 cells:safety test of CD33-CARNK-92 cells in patients with relapsed and refractory acute myeloid leukemia［J］.Am J Cancer Res，2018，8(6):1083-1089.
[36]OMOLE AE，FAKOYA AOJ.Ten years of progress and promise of induced pluripotent stem cells:historical origins,characteristics,mechanisms,limitations,and potential applications［J］.Peer J，2018，6:e4370.
[37]LI Y，Hermanson DL，Moriarity BS，et al.Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity［J］.Cell Stem Cell，2018，23(2):181-192.

Memo

Memo:
上海市优秀学科带头人项目（编号：18XD1424000）;上海卫生计生委重点项目（编号：201640020）;上海市科委西医引导项目（编号：17411967300）
Last Update: 1900-01-01